Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $656.81 million. The enterprise value is $561.66 million.
Important Dates
The last earnings date was Friday, November 7, 2025, before market open.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 177.04 million shares outstanding. The number of shares has increased by 25.86% in one year.
| Current Share Class | 177.04M |
| Shares Outstanding | 177.04M |
| Shares Change (YoY) | +25.86% |
| Shares Change (QoQ) | +24.24% |
| Owned by Insiders (%) | 15.05% |
| Owned by Institutions (%) | 44.49% |
| Float | 104.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 85.14 |
| Forward PS | 38.39 |
| PB Ratio | 4.05 |
| P/TBV Ratio | 4.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 93.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.61, with a Debt / Equity ratio of 0.73.
| Current Ratio | 6.61 |
| Quick Ratio | 6.09 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -112.34% and return on invested capital (ROIC) is -49.92%.
| Return on Equity (ROE) | -112.34% |
| Return on Assets (ROA) | -35.52% |
| Return on Invested Capital (ROIC) | -49.92% |
| Return on Capital Employed (ROCE) | -58.28% |
| Revenue Per Employee | $27,930 |
| Profits Per Employee | -$922,145 |
| Employee Count | 214 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.41% in the last 52 weeks. The beta is 2.65, so Prime Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.65 |
| 52-Week Price Change | +11.41% |
| 50-Day Moving Average | 4.91 |
| 200-Day Moving Average | 3.15 |
| Relative Strength Index (RSI) | 42.63 |
| Average Volume (20 Days) | 4,091,737 |
Short Selling Information
The latest short interest is 18.60 million, so 10.51% of the outstanding shares have been sold short.
| Short Interest | 18.60M |
| Short Previous Month | 18.21M |
| Short % of Shares Out | 10.51% |
| Short % of Float | 17.83% |
| Short Ratio (days to cover) | 4.74 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $5.98 million and -$197.34 million in losses. Loss per share was -$1.44.
| Revenue | 5.98M |
| Gross Profit | -154.05M |
| Operating Income | -203.96M |
| Pretax Income | -197.34M |
| Net Income | -197.34M |
| EBITDA | -196.80M |
| EBIT | -203.96M |
| Loss Per Share | -$1.44 |
Full Income StatementBalance Sheet
The company has $213.29 million in cash and $118.14 million in debt, giving a net cash position of $95.15 million or $0.54 per share.
| Cash & Cash Equivalents | 213.29M |
| Total Debt | 118.14M |
| Net Cash | 95.15M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 161.82M |
| Book Value Per Share | 0.92 |
| Working Capital | 196.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$109.06 million and capital expenditures -$6.03 million, giving a free cash flow of -$115.10 million.
| Operating Cash Flow | -109.06M |
| Capital Expenditures | -6.03M |
| Free Cash Flow | -115.10M |
| FCF Per Share | -$0.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -3,412.48% |
| Pretax Margin | -3,301.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.86% |
| Shareholder Yield | -25.86% |
| Earnings Yield | -30.05% |
| FCF Yield | -17.52% |
Analyst Forecast
The average price target for Prime Medicine is $9.31, which is 150.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.31 |
| Price Target Difference | 150.94% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 18.63% |
| EPS Growth Forecast (5Y) | -13.93% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of -3.1 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.1 |
| Piotroski F-Score | 4 |
